Internal shingles is generally not contagious in the way typical shingles is. Standard shingles spreads through direct contact with fluid from open blisters or by breathing in virus particles released from those blisters. Since internal shingles (medically called zoster sine herpete) produces no visible blisters on the skin, the primary transmission route is essentially absent. That said, the same virus is active inside the body, so the picture is more nuanced than a simple “no.”
How Shingles Normally Spreads
The varicella-zoster virus, the same virus behind chickenpox, causes shingles when it reactivates from the nerves where it has been dormant. In typical shingles, fluid-filled blisters form on the skin, and those blisters are the main source of contagion. The CDC notes that people with shingles cannot spread the virus before blisters appear or after the rash scabs over. The window of contagion is tied directly to the presence of open, weeping lesions.
Someone who catches the virus from a shingles patient doesn’t get shingles. They get chickenpox, assuming they’ve never had it or been vaccinated. The virus travels through direct contact with blister fluid or through airborne particles shed from the blisters.
Why Internal Shingles Is Different
Internal shingles happens when the virus reactivates in nerves that don’t connect to the skin. Instead, it affects the enteric nervous system, which controls internal organs like the liver, pancreas, and intestines. Because the virus never reaches the skin surface, there are no blisters to shed viral particles from.
Without those blisters, the two established transmission routes (skin contact and airborne blister particles) are effectively cut off. This makes internal shingles far less likely to be contagious than the classic form. However, varicella-zoster can also be found in respiratory secretions and saliva during reactivation. While the CDC emphasizes blister fluid as the primary transmission source, the theoretical possibility of low-level viral shedding through other routes hasn’t been fully ruled out in every case.
The practical takeaway: someone with internal shingles poses a dramatically lower transmission risk than someone with a visible shingles rash, but people who are pregnant, immunocompromised, or have never had chickenpox should still exercise caution around anyone with an active varicella-zoster infection.
Recognizing Internal Shingles
Internal shingles is tricky because the hallmark sign of shingles, the painful blistering rash, never appears. Instead, symptoms depend on which nerves and organs are involved. Visceral disseminated varicella-zoster infection causes severe abdominal pain in 80 to 100 percent of cases, resulting from inflammation of organs like the liver, pancreas, and intestines. The pain can mimic appendicitis, pancreatitis, or other acute abdominal emergencies.
Other possible symptoms include nerve pain along a specific body region without any skin changes, headaches or neurological symptoms if the virus affects nerves near the brain, and general malaise or fever. Because there’s no rash to point to, many people go weeks without a correct diagnosis.
How It’s Diagnosed Without a Rash
Diagnosing internal shingles is challenging precisely because the most useful test, PCR (a DNA detection method), works best on samples from skin lesions like blisters or scabs. When there are no skin lesions to sample, doctors must rely on less ideal specimens: saliva, cerebrospinal fluid, blood, or urine. These samples are more likely to produce false negatives.
Blood antibody tests can confirm a recent varicella-zoster infection, but they can’t distinguish between a first infection and a reactivation. Measuring changes in antibody levels over time has limited value for diagnosing shingles specifically. In practice, diagnosis often comes down to a combination of symptoms, clinical judgment, and whatever lab evidence is available. This is one reason internal shingles is likely underdiagnosed.
Who Is Most at Risk
Internal shingles disproportionately affects people whose immune systems are weakened. The CDC identifies several high-risk groups: organ transplant recipients, people with cancers like leukemia and lymphoma, people living with HIV, and those taking immunosuppressive medications including steroids. About 30 percent of people hospitalized with any form of shingles have a compromised immune system.
Older adults are also at elevated risk, even without an underlying immune condition. The immune system’s ability to keep the dormant virus in check naturally declines with age, which is why shingles of all types becomes more common after 50.
Treatment and What to Expect
Internal shingles is treated with the same antiviral medications used for typical shingles. Starting treatment within 72 hours of symptom onset is ideal because antivirals work by limiting the virus’s ability to replicate. In people with healthy immune systems, treatment typically lasts about 7 days. For those with weakened immunity, treatment continues for at least 10 to 14 days or until the infection has fully resolved, whichever takes longer.
Severe cases, particularly in immunocompromised patients, may require intravenous antiviral therapy in a hospital setting. Pain management is also a significant part of treatment, since the nerve pain from internal shingles can be intense and persistent. Some people develop postherpetic neuralgia, a condition where nerve pain lingers for months or even years after the active infection clears.
Vaccine Protection
The Shingrix vaccine is over 90 percent effective at preventing shingles in adults 50 and older with healthy immune systems. In adults between 50 and 69, effectiveness reaches 97 percent. For adults 70 and older, it drops slightly to 91 percent. In people with weakened immune systems, effectiveness ranges from 68 to 91 percent depending on the specific condition.
The vaccine also protects against postherpetic neuralgia, with about 89 to 91 percent effectiveness depending on age. While vaccine studies primarily measured prevention of typical shingles with a rash, the vaccine targets the same underlying viral reactivation that causes internal shingles. Preventing the virus from reactivating in the first place is the most reliable way to avoid both forms of the disease.